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Summary: Molecular genetic testing is part of modern
medical practice. DNA tests are an essential part of diagnos-
tics and genetic counseling in single gene diseases, while
their application in polygenic disorders is still limited. Phar -
ma cogenetics studies DNA variants associated with varia-
tions in drug efficacy and toxicity, and tests in this field are
being deve loped rapidly. The main method for molecular
genetic testing is the polymerase chain reaction, with a num-
ber of modifications. New methods, such as next generation
sequencing and DNA microarray, should allow simultaneous
analysis of a number of genes, even whole genome sequenc-
ing. Ethical concerns in molecular genetic testing are very
important, along with legislation. After molecular genetic
testing, interpretation of results and genetic counseling
should be done by professionals. With the example of throm-
bophilia, we discuss questions about genetic testing, its pos-
sibilities and promises.
Keywords: molecular genetics, test, methods, genetic
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Kratak sadr`aj: Molekularno geneti~ki testovi su deo
savremene medicinske prakse. Primenjuju se pre svega u
dijagnostici i geneti~kom savetovanju kod monogenskih
bolesti, dok su kod poligenskih poreme}aja jo{ uvek u
razvoju. Farmakogenetski testovi su vezani za ulogu DNK
varijanti u razli~itom odgovoru na terapiju i ve} dobijaju
punu afirmaciju. Metode izvo|enja molekularno geneti~kih
testova su bazirane na reakciji lan~ane polimerizacije DNK
(PCR) i njenim modifikacijama. Nove metode, kao {to su
slede}a generacija sekvenciranja i primena genskih ~ipova,
omogu}i}e simultano dobijanje velikog broja podataka o
ispitivanoj DNK, pa ~ak i analizu ~itavog genoma. Mol e -
kularno geneti~ko testiranje je povezano sa striktnim eti~ -
kim postulatima, koji su i zakonski regulisani. Tuma~enje
rezultata testiranja i sledstveni geneti~ki savet treba da da
profesionalac. Na primeru trombofilije iznosimo savremene
stavove o geneti~kom testiranju, razmatramo njegove mo -
gu}nosti i nove smernice. 
Klju~ne re~i: molekularna genetika, testovi, metode, ge -
neti~ko savetovanje
Introduction
Molecular genetic tests are defined as any
analysis of genetic material that helps to establish
diagnosis, choice of treatment, long term follow-up
of a patient and family counseling. Nowadays, these
tests are an integral part of medicine, available for a
large number of human disorders, including single
gene diseases, polygenic diseases and chromosomal
syndromes (1, 2). 
In the case of single gene disorders, molecular
tests provide exact detection of genetic changes in
symptomatic patients, as well as in asymptomatic or
presymptomatic carriers. Genetic testing is an essen-
tial part of prenatal, even pre-implantation diagnosis
also, usually based on a specific DNA change detect-
ed in an index patient. Even molecular testing of post
mortem material sometimes helps in establishing a
diagnosis and genetic counseling for a family. At this
moment, more than 3000 single gene diseases are
known, and for the majority of them molecular ge -
netic tests are available. The direct approach in test-
ing is predominant, which comprises exact analysis of
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the disease-causing gene with precise detection of the
mutation. However, in some cases, direct analysis is
not possible, usually due to technical/technological
deficiencies. Then, indirect molecular genetic analysis
tries to provide the necessary information. Indirect
analysis is a family-based study of polymorphic mark-
ers closely linked to the disease gene. Such studies
have lower sensitivity compared to direct ones, be -
cause of the possibility of separation between markers
and the disease-causing mutation during DNA re -
combi na tion; expected percentage of error should be
≤2% (1, 2). 
Polygenic or multifactor diseases are the result of
interaction between a genetic base (represented by a
number of genes) and environmental factors. So, in
this field, the focus of molecular testing is on suscep-
tibility genes, i.e. gene polymorphisms that predispose
to disease. Despite massive efforts and the large num-
ber of conducted associative and candidate-gene
studies, progress in this area is not so impressive and
strong susceptibility genes have been detected for a
small proportion of disorders (3–7). Today, there are
only a few genetic tests for polygenic disorders in me d -
ical practice, such as thrombophilia testing (8). 
A new and promising field of application for mo -
lecular genetic tests is pharmacogenetics. Pharmaco -
genetics studies DNA variants associated with varia-
tions in drug efficacy and toxicity, with the final goal of
developing personalized therapy, tailored for a parti cu -
lar individual. Pharmacogenetic tests are now avail-
able for a number of drugs, and they have been ra pid -
ly and widely adopted into clinical practice. Moreover,
genotyping to predict drug response has the potential
to become more widespread than genotyping to pre-
dict risk (9, 10). 
Methods of molecular genetic testing 
Many different methods of DNA analysis have
been described and applied. In every laboratory, a
method is chosen based on the required sensitivity,
necessary equipment, number of samples and eco-
nomic capacity (1, 2). Genomic DNA is required for
genetic analysis, but quantity and quality of DNA
preparation may vary, depending on the requirements
of the assay. Majority of laboratories routinely purify
DNA for the analysis, using some of the manual
methods or commercial kits. The source of DNA
could be any tissue with nuclear cells: usually, it is
blood or bucal swab; in prenatal diagnosis these are
chorionic villi samples, cells from amniotic fluid etc
(1, 2, 10). 
Most of the methods of molecular genetic analy-
sis are based on amplification of the DNA region of
interest by the polymerase chain reaction (PCR), using
synthetic oligonucleotide primers and the enzyme Taq
polymerase. PCR with a number of its modifications
has been the golden standard in molecular genetic
testing for more than 20 years (10). An important and
innovative modification of standard PCR is Real Time
PCR, which provides elegant and effective quantifica-
tion or genotypisation of the tested material. Detection
of the amplification range in real time is enabled by
the measurement of increasing fluorescence from dye
linked to DNA. In some cases, however, time consum-
ing classic tests of hybridization (Southern blotting, dot
blot) are still the methods of choice. Recently, the
MLPA (multiplex ligation-dependent probe amplifica-
tion) method has been developed as rapid and effec-
tive for detection of gene deletions/duplications as
well as targeted substitutions. Since 2003, several
hundred commercial MLPA assays have been avail-
able for routine usage. 
Direct DNA sequencing, as an extremely sophis-
ticated method of analysis, gives exact data about the
primary structure of a particular DNA segment. Clas -
sic, famous and well established is Sanger’s method
of sequencing, but in the last few years several new
platforms of »next generation sequencing« (NGS)
have been developed, in order to provide faster and
cheaper sequencing analyses (11, 12). The available
personal whole genome/exome sequencing is one of
the NGS goals, likely to be achieved in the next few
years. Microarray format of DNA testing is also tech-
nically sophisticated, modern and has perspective,
allowing more than 100.000 simultaneous micro-
hybridization tests in one assay. Gene chips created
for molecular genetic testing of some groups of dis-
eases are based on this method (13).    
Ethical concerns and interpretation 
of results
From an ethical point of view, in molecular
genetic testing the issues of confidentiality and priva-
cy, the use of individual-specific information and pro-
tection of individual rights are of general interest. It is
postulated that the results of genetic tests should be
confidential, and could not be used for discrimination
in health insurance, or education and job opportuni-
ties. Vulnerable groups, such as children, should be
particularly protected (14, 15). It is necessary to
emphasize that the results obtained by DNA-based
methods show very high specificity and sensitivity.
However, for exact interpretation of results, good
knowledge of the genetic basis of disease is neces-
sary. For example, a negative result could be a conse-
quence of the genetic heterogeneity of disease or
method limitations. 
Molecular genetic diagnostics: State-of-the-art in
Serbia 
In Serbia, the molecular genetic service is well- 
-de veloped, with almost 20 years of experience. How -
ever, this kind of tests is not yet covered by health
insurance. According to recommendations for de ve l -
oping countries, Serbian geneticists perform mo le -
cular genetic diagnostics of cystic fibrosis, Duchenne/
Becker muscular dystrophy, trinucleotide repeat disor-
ders, spinal muscular atrophy, hemoglobinopathies,
and male infertility, as well as thrombo philia testing,
and a number of neurogenetic and phar macogenetic
tests. Some laboratories are members of different
quality control networks, with inter-laboratory and
external – foreign checking (www.dgsgenetika.org.rs/
sekcije-medicinska-genetika).   
The example of thrombophilia
Genetic testing in thrombophilia is a good
example of the power, specificity and sensitivity of
molecular genetic testing in disease management.
Standard genetic testing in thrombophilia
By definition, thrombophilia is increased tenden-
cy to develop thrombosis and its clinical manifesta-
tions, which are familial, recurrent or unusual in age
and site of occurrence. Prothrombotic phenotype
results from the interaction of genetic predisposing
factors and »clinical« risk factors such as obesity,
immobility, major and minor surgery, hormone thera-
py, malignancy, etc (16). The most common congen-
ital disorders associated with thrombophilia are: a
deficiency of anti thrombin, protein C and protein S,
variants of factor V Leiden and prothrombin 20210,
and mild hyperhomocysteinemia. Individually or in
combination, these traits are present in about 40% of
patients with venous thromboembolism, and in
approximately the same percentage of women with
disorders of pregnancy and puerperium, such as fetal
loss, fetal growth restriction and preeclampsia (17).
Direct molecular genetic detection of genetic
thrombophilia risk factors including factor V Leiden,
prothrombin G20210A, and MTHFR (methyl en e-
tetrahydrofolate-reductase) C677T mutations is of fer -
ed by many clinical diagnostic laboratories (16–18).
The Laboratory of Molecular Genetics at the Insti tute
of Human Genetics, University of Belgrade School of
Medicine, Bel grade, in cooperation with the Clinic of
Hematology and Neurology Clinic, Clinical Center of
Serbia, have been performing these analyses for one
decade.
New data about the genetics of thrombophilia
In order to determine new genetic markers of
thrombophilia, beside the analysis of candidate ge nes,
genome-wide association studies (GWAS) have been
performed. Recent family-based GWAS showed new
association of locus rs973117 with hyperhomocys-
teinemia, which is considered to be an independent
prothrombotic risk factor (19). This association was
independent of known confounders, including creati-
nine clearance and plasma fibrinogen concentration.
Polymorphism rs973117 is located on chromosome
9, near the PTPRD gene which encodes for receptor-
type tyrosine-protein phosphatase delta, a member of
the protein tyrosine phosphatase (PTP) family. PTPs
are known to be signaling molecules that regulate a
variety of cellular processes including cell growth, dif-
ferentiation, mitotic cycle, and oncogenic transfor -
mation, but no previous data on their involvement in
homocysteine metabolism exist. In the cited multicen-
tric GWAS study, rs973117 A allele was asso ciated
with a higher homocysteine level in the cohorts GAIT
(Genetic Analysis of Idiopathic Thrombophilia) and
PROCARDIS (Precocious Coronary Artery Di sease). 
In our investigation, we have analyzed the asso-
ciation of polymorphism rs973117 and plasma
homo cysteine level in a group of Serbian patients with
cerebrovascular insult (CVI). Our group consisted of
72 patients (mean age 53.75 y) with no other signi -
ficant CVI risk factors. Plasma homocysteine level was
measured by the HPLC (high pressure liquid chro-
matography) method. Genotyping of the rs973117
locus was performed by the Real-Time PCR method
(ABI 7500 RT PCR System), using the predesigned
TaqMan genotyping assay (Life Technologies, USA)
(Figure 1). Initially, we found no significant associa-
tion of rs973117 genotypes and plasma homocys-
teine (p=0.898) (Figure 2). Mean homocysteine level
was 14.44±6.92, 14.67±4.57 and 15.18±5.00
mmol/L in the AA, AC and CC genotype, respectively.
However, in the group of patients under 50 y of age,
a significantly higher homocysteine level in individu-
als with the rs973117 CC genotype has been detect-
ed (p=0.007). Our results confirm the role of the
PTPRD gene as a novel determinant of plasma homo-
cysteine and implicate new pathways in homocysteine
meta bo lism, as well as new thrombophilia suscepti -
bility loci.
Pharmacogenetics of thrombophilia
Among anticoagulant drugs, warfarin has been
the standard of care for more than 50 years to pre-
vent and treat thromboembolism. One of the major
problems with its use in clinical practice is large in ter-
individual variability in dosage requirement. Pharma -
co genetic studies showed that polymorphisms in
genes VKORC1, CYP2C9, and CYP4F2 are responsi-
ble for this variability, and a genome-wide association
study confirmed their role (20–22). VKORC1 (vitamin
K epoxide reductase complex 1) is the target enzyme
inhibited by warfarin, resulting in interruption of the
recycling of vitamin K in the liver, and CYP enzymes
are responsible for the metabolic clearance of S-war-
farin, the more potent isomer of warfarin. It is estab-
lished that approximately 30% of the dose variance is
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explained by single nucleotide polymorphisms (SNPs)
in the VKORC1 and another approximately 12% by
two non-synonymous SNPs (*2, *3) in the CYP2C9
gene. Other important factors include: age, dietary
vitamin K intake, the presence of other comorbidities
and interaction with other drugs. A number of studies
have shown that algorithms for warfarin dosing that
incorporate pharmacogenomic information are better
than those using clinical data alone. However, some
experts think that routine genetic testing before war-
farin initiation should not be recommended (23).
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Figure 2 Mean plasma homocysteine levels (in mmol/L) in different rs973117 genotypes.
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